APOE and Alzheimer disease: Based on previous literature [4, 7, 8, 10–23] and data availability, we evaluated in this large multicenter study the impact of demographic (age and sex), clinical (Mini-Mental State Examination [MMSE]), genetic (apolipoprotein [APOE] genotype), and imaging (cortical thickness, white matter hyperintensities [WMH], and amyloid-β [Aβ] status) variables on tau PET status across persons with AD dementia, mild cognitive impairment (MCI), and non-AD neurodegenerative disorders, and cognitively unimpaired (CU) individuals.